Clinical trials: Metastatic Malignant Neoplasm to Brain
NSCLC, Brain Metastases
Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis
REPOSE is a phase II clinical trial exploring the safety and efficacy of repotrectinib in patients with non-small cell lung cancer (NSCLC) characterized by the presence of brain metastasis (BM) and whose tumors have mutated ROS…
- Conditions
- NSCLC, Brain Metastases, ROS1 Gene Rearrangement
- Trial name
- REPOSE (NCT06315010)
- Testing
- Repotrectinib
- Where
- 17 sites in Austria, Germany and 1 more
- Volunteers
- 20 people
- Sponsor
- MedSIR
Brain Metastases
Phase I Study of Fractionated Stereotactic Radiation Therapy
There is a lack of prospective trial data and consensus guidelines describing the use of Fractionated Stereotactic Radiation Therapy (FSRT) in the treatment of brain metastases.
- Trial name
- NCT03726359
- Testing
- Fractionated Stereotactic Radiation Therapy (FSRT)
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Albert Einstein College of Medicine
Breast Cancer
A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer
This single-arm, multicenter, open-label study will evaluate the efficacy and safety of Herceptin (trastuzumab) in combination with whole brain radiotherapy on brain metastases in patients with HER-2 positive breast cancer.
- Trial name
- NCT01363986
- Testing
- trastuzumab [Herceptin]
- Where
- 16 sites in Italy
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer, Melanoma
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
The primary objective of the study is to assess the efficacy in terms of CNS-specific PFS of the combination of standard systemic treatment plus SRS vs.
- Trial name
- USZ-STRIKE (NCT05522660)
- Testing
- Stereotactic radiosurgery, Immune checkpoint inhibitor
- Where
- 15 sites in Italy, Netherlands and 3 more
- Volunteers
- 180 people
- Sponsor
- ETOP IBCSG Partners Foundation
Non-small Cell Lung Cancer Metastatic
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
Objective:Patients with asymptomatic or minimally symptomatic Stage IV EGFR-positive NSCLC with baseline intracranial metastases.
- Trial name
- NCT05800223
- Testing
- Almonertinib, SBRT
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Cancer Hospital, China
Brain Tumors
ALA-induced PpIX Fluorescence During Brain Tumor Resection
Removing a tumor from a patients brain is hard to do because, very often, brain tumors do not have boundaries that are easy for the patients surgeon to find.
- Trial name
- NCT02191488
- Testing
- 5-aminolevulinic acid
- Where
- United States
- Volunteers
- 540 people
- Sponsor
- David W. Roberts
Tumors Metastatic to Brain
Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- NCT01276210
- Testing
- sorafenib tosylate, stereotactic radiosurgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Brain Tumor, Primary, Brain Tumor - Metastatic
Clinical Feasibility of Brain Radiotherapy Using Synthetic CTs in an MRI-only Workflow
The goal of this observational study is to show the feasibility of an MRI-only workflow in brain radiotherapy. The main question it aims to answer is: Is an MRI-only workflow based on deep learning sCTs feasible in clinical…
- Trial name
- NCT06106997
- Testing
- brain radiotherapy
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Non-small Cell Lung Cancer
The Continuation of Erlotinib
Newly developed or progressive brain metastasis during erlotinib treatment is considered progressive disease requiring change of treatment regimens despite no progression in extracranial lesions.
- Trial name
- NCT01130779
- Testing
- Erlotinib (TARCEVA®)
- Where
- South Korea
- Volunteers
- 23 people
- Sponsor
- Samsung Medical Center
Metastatic Melanoma
A Study of LN-144 in People With Metastatic Melanoma to the Brain
This is an open label study evaluating lifileucel (LN-144) in patients with melanoma brain metastases.
- Trial name
- NCT05640193
- Testing
- Lifileucel (LN-144)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Neoplasms
Local Radiotherapy Following Complete Resection of a Brain Metastasis
Objective: To improve local control following complete resection of a single brain metastasis using fractionated local stereotactic radiotherapy, whilst maintaining neurological functioning, neurocognition and quality of life.
- Trial name
- NCT02729558
- Testing
- local SRT
- Where
- 2 sites in Netherlands
- Volunteers
- 70 people
- Sponsor
- Amsterdam UMC, location VUmc
Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
The goal of this phase II clinical trial] is to analyze the efficacy of patritumab deruxtecan (HER3-DXd) in patients with metastatic breast cancer (MBC) or advanced non-small cell lung cancer (aNSCLC) with active brain metastases…
- Conditions
- Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult
- Trial name
- TUXEDO-3 (NCT05865990)
- Testing
- Patritumab deruxtecan
- Where
- 8 sites in Austria, Spain
- Volunteers
- 63 people
- Sponsor
- MedSIR
Brain Metastases
Evaluation of Brain Metastases Treated With Stereotactic Radiotherapy Using Dynamic [18F]FDG PET
The purpose of this study is to evaluate the clinical usefulness of dynamic [18F]FDG PET imaging in assessing brain metastasis post stereotactic radiotherapy to separate true progression from the treatment-related changes.
- Trial name
- NCT06511323
- Testing
- dynamic [18-FDG PET] scan post stereotactic radiation for brain metastases
- Volunteers
- 70 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Brain Cancer, Neoplasm Metastasis
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLCA) brain metastases in patient with 1-4…
- Conditions
- Brain Cancer, Neoplasm Metastasis, Lung Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00946673
- Testing
- Vorinostat, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
NSCLC, EGFR Activating Mutation
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
This study is to evaluate the efficacy and safety of TY-9591 in first-line treatment of patients with EGFR-sensitive mutation-positive non-small cell lung cancer with brain metastases compared to Osimertinib.
- Conditions
- NSCLC, EGFR Activating Mutation, Brain Metastases
- Trial name
- NCT05948813
- Testing
- TY-9591, Osimertinib
- Where
- China
- Volunteers
- 420 people
- Sponsor
- TYK Medicines, Inc
Quality of Life, Brain Metastases
Evaluation of the Best Treatment in Terms of Quality of Life for Patients Having a Brain Metastasis
Main Goal : evaluation of quality of life for patient having a brain metastasis and allowed to have either surgery and radiosurgery of the surgical site or only hypofractionned radiosurgery on the lesion.
- Trial name
- OPTMETACER (NCT04358666)
- Testing
- surgery and focal radiosurgery of the surgical bed
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Caen
Breast Cancer
Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis
Basis: Brain metastasis is very common in breast cancer, and HER2 positivity is a risk factor for high incidence of brain metastasis, with approximately 50% of HER2+ MBC cases experiencing brain metastasis.
- Trial name
- NCT06015113
- Testing
- Disitamab Vedotin plus pyrotinib or naratinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xi'an International Medical Center Hospital
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
This is a clinical study to compare the efficacy and safety of HBI-8000 combined with nivolumab to Placebo combined with nivolumab in patients with unresectable or metastatic melanoma.
- Trial name
- NCT04674683
- Testing
- HBI-8000 in combination with nivolumab
- Where
- 139 sites in United States, Australia and 15 more
- Volunteers
- 450 people
- Sponsor
- HUYABIO International, LLC.
Brain Metastases
Study of Temozolomide to Treat Newly Diagnosed Brain Metastases
The purpose of this study is to determine if administering temozolomide after completion of stereotactic radiosurgery helps control existing brain metastases and prevents the developement of new brain metastases.
- Trial name
- NCT00717275
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Florida
HER2 Positive Breast Cancer
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
This study is being done to see if tucatinib works better than placebo to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma.
- Trial name
- HER2CLIMB (NCT02614794)
- Testing
- tucatinib, capecitabine, trastuzumab
- Where
- 176 sites in United States, Australia and 13 more
- Volunteers
- 612 people
- Sponsor
- Seagen Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.